132 related articles for article (PubMed ID: 19565364)
1. Acute renal failure related to oxaliplatin-induced intravascular hemolysis.
Ulusakarya A; Misra S; Haydar M; Habert H; Castagne V; Gumus Y; Delmas-Marsalet B; Machover D
Med Oncol; 2010 Dec; 27(4):1425-6. PubMed ID: 19565364
[TBL] [Abstract][Full Text] [Related]
2. A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.
Ito I; Ito Y; Mizuno M; Suzuki Y; Yasuda K; Ozaki T; Kosugi T; Yasuda Y; Sato W; Tsuboi N; Maruyama S; Imai E; Matsuo S
Clin Exp Nephrol; 2012 Jun; 16(3):490-4. PubMed ID: 22450906
[TBL] [Abstract][Full Text] [Related]
3. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer.
Alberts SR; Sinicrope FA; Grothey A
Clin Colorectal Cancer; 2005 Sep; 5(3):211-3. PubMed ID: 16197625
[No Abstract] [Full Text] [Related]
4. Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.
Lai JI; Wang WS; Lai YC; Lin PC; Chang SC
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):425-8. PubMed ID: 20557834
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis.
Sørbye H; Bruserud Y; Dahl O
Acta Oncol; 2001; 40(7):882-3. PubMed ID: 11859992
[No Abstract] [Full Text] [Related]
6. Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
Sonnenblick A; Meirovitz A
Int J Clin Oncol; 2010 Aug; 15(4):420-2. PubMed ID: 20217448
[TBL] [Abstract][Full Text] [Related]
7. A case of 5-fluorouracil-induced acute psychosis.
Fora A; Alabsi E; Fakih M
Clin Colorectal Cancer; 2009 Jul; 8(3):166-8. PubMed ID: 19632932
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer.
Malkhasyan K; Halene S; Lacy J
Clin Colorectal Cancer; 2015 Mar; 14(1):e9-e12. PubMed ID: 25446051
[No Abstract] [Full Text] [Related]
9. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
Arnold D; Höhler T; Dittrich C; Lordick F; Seufferlein T; Riemann J; Wöll E; Herrmann T; Zubel A; Schmoll HJ
Ann Oncol; 2008 Aug; 19(8):1442-1449. PubMed ID: 18441330
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Bokemeyer C; Bondarenko I; Makhson A; Hartmann JT; Aparicio J; de Braud F; Donea S; Ludwig H; Schuch G; Stroh C; Loos AH; Zubel A; Koralewski P
J Clin Oncol; 2009 Feb; 27(5):663-71. PubMed ID: 19114683
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
14. A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Lee SS; Kim MK; Sym SJ; Lee JS; Kang YK
J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S98-S103. PubMed ID: 17923763
[TBL] [Abstract][Full Text] [Related]
15. [A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil].
Ojima E; Nakano T; Kanamoto A; Sasaki S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1962-4. PubMed ID: 24393980
[TBL] [Abstract][Full Text] [Related]
16. Acute immune hematological complication of oxaliplatin. A series of 3 cases.
Garciaz S; Oziel-Taieb S; Dermeche S; Ries P; Vessaud J; Raoul JL
Tumori; 2014; 100(1):e17-9. PubMed ID: 24675502
[TBL] [Abstract][Full Text] [Related]
17. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S
Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329
[No Abstract] [Full Text] [Related]
18. The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.
Reddy GK
Clin Colorectal Cancer; 2005 Jan; 4(5):300-1. PubMed ID: 15663832
[No Abstract] [Full Text] [Related]
19. [Systemic therapy for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
[TBL] [Abstract][Full Text] [Related]
20. Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Gibson TB; Grothey E; Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):233-9. PubMed ID: 18650191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
